Prognostic nutritional index as a prognostic marker in glioblastoma: Data from a cohort of 282 Italian patients.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 May 2019
Historique:
received: 04 01 2019
revised: 06 03 2019
accepted: 01 04 2019
pubmed: 12 4 2019
medline: 5 6 2020
entrez: 12 4 2019
Statut: ppublish

Résumé

Preoperative prognostic nutritional index (PNI) is linked to the clinical outcome of patients with malignant tumours, however few studies have investigated its utility in predicting outcome in glioblastoma multiforme (GBM). We performed a retrospective study on adult patients with GBM in order to evaluate the impact of PNI on overall survival (OS), after adjusting for known prognostic factor (age, extent of surgery, Karnofsky performance status, radiochemotherapy). This is an Italian, multicentre, retrospective, cohort study. The patient's cohort includes 282 individuals with a newly diagnosed GBM followed in 3 Lombardia Hospitals In all cases the diagnosis was supported by histological data. Patient's information including sex, age at onset, Karnofsky performance status (KPS), extension of surgical resection (EOR), adjuvant treatment, antiepileptic treatment, serum variables and survival data were collected. Univariate and multivariate analysis did not reveal an association between PNI and overall survival in our series of GBM patients. PNI is a controversial marker for prognosis in GBM patients and further prospective studies are necessary to elucidate its role.

Identifiants

pubmed: 30974322
pii: S0022-510X(19)30159-5
doi: 10.1016/j.jns.2019.04.002
pii:
doi:

Substances chimiques

Anticonvulsants 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-179

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Andrea Rigamonti (A)

Neurological Department, ASST Lecco, Via Dell' Eremo 9-11, 23900 Lecco, Italy. Electronic address: andrea.rigamonti@asst-lecco.it.

Francesca Imbesi (F)

Neurological Department, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20162 Milano, Italy.

Antonio Silvani (A)

Neuro Oncology Unit, Fondazione IRCSS Carlo Besta, Via Celoria 11, 20133 Milano, Italy.

Elena Lamperti (E)

Neuro Oncology Unit, Fondazione IRCSS Carlo Besta, Via Celoria 11, 20133 Milano, Italy.

Elio Agostoni (E)

Neurological Department, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20162 Milano, Italy.

Luca Porcu (L)

Pharmacological Research Institute IRCSS Mario Negri, Via La Masa 19, 20156 Milano, Italy.

Irene De Simone (I)

Pharmacological Research Institute IRCSS Mario Negri, Via La Masa 19, 20156 Milano, Italy.

Valter Torri (V)

Pharmacological Research Institute IRCSS Mario Negri, Via La Masa 19, 20156 Milano, Italy.

Emilio Ciusani (E)

Laboratory of Clinical Pathology and Medical Genetics, Fondazione IRCSS Carlo Besta, Via Celoria 11, 20133 Milano, Italy.

Claudio Bonato (C)

Department of Clinical Laboratory, ASST Lecco, Via Dell' Eremo 9-11, 23900 Lecco, Italy.

Andrea Salmaggi (A)

Neurological Department, ASST Lecco, Via Dell' Eremo 9-11, 23900 Lecco, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH